Generic drug: omacetaxine mepesuccinate
Brand name: Synribo
What is Synribo (omacetaxine mepesuccinate), and how does it work?
- that is in the chronic phase or accelerated phase, and
- who have not responded to (resistant) or cannot tolerate 2 or more medicines called tyrosine kinase inhibitors.
It is not known if Synribo is safe and effective in children.
What are the side effects of Synribo?
Synribo can cause serious side effects including:
- Low blood counts. Low blood counts are common when
using Synribo, including low red blood cells, white blood cells, and platelets,
and can be severe. If your white blood cell count becomes very low, you are at
increased risk for infection which can lead to death. Your healthcare provider
will check your blood counts regularly during treatment with Synribo. Tell your
healthcare provider right away if you get any of the following symptoms:
- Bleeding. Synribo causes severe low platelet
counts that may increase your risk of severe bleeding. Severe low platelet
counts can cause you to have bleeding in your brain that can lead to death, or
severe stomach bleeding. Your healthcare provider will check your platelet
counts regularly during treatment with Synribo. Tell your healthcare provider
right away if you get any of the following symptoms:
The most common side effects of Synribo include:
- redness, swelling, or pain at injection site; and
You may have hair loss during treatment with Synribo.
Synribo may cause fertility problems in males, which may affect your ability to
have children. Talk to your healthcare provider if this is a concern for you.
These are not all of the side effects of Synribo.
Call your doctor for medical advice about side effects.
You may report side effects to FDA at 1-800-FDA-1088.
What is the dosage for Synribo?
- The recommended starting schedule for induction is 1.25
mg/m² administered subcutaneously twice daily at approximately 12 hour
intervals for 14 consecutive days every 28 days, over a 28-day cycle.
should be repeated every 28 days until patients achieve a hematologic response.
- The recommended maintenance schedule is 1.25 mg/m² administered
subcutaneously twice daily at approximately 12 hour intervals for 7 consecutive
days every 28 days, over a 28-day cycle.
- Treatment should continue as long as
patients are clinically benefiting from therapy.
Dose Adjustments And Modifications
- Synribo treatment cycles may be delayed and/or the number of days of dosing
during the cycle reduced for hematologic toxicities (e.g. neutropenia,
- Perform complete blood counts (CBCs) weekly during
induction and initial maintenance cycles.
- After initial maintenance cycles,
monitor CBCs every two weeks or as clinically indicated.
- If a patient
experiences Grade 4 neutropenia (absolute neutrophil count (ANC) less than 0.5
x 109/L) or Grade 3 thrombocytopenia (platelet counts less than 50 x 109/L)
during a cycle, delay starting the next cycle until ANC is greater than or
equal to 1.0 x 109/L and platelet count is greater than or equal to 50 x 109/L.
Also, for the next cycle, reduce the number of dosing days by 2 days (e.g. to
12 or 5 days).
- Manage other clinically significant non-hematologic
toxicity symptomatically. Interrupt and/or delay Synribo until toxicity is
What drugs interact with Synribo?
No Information provided
Is Synribo safe to use while pregnant or breastfeeding?
- Based on its mechanism of action and findings from animal studies,
Synribo can cause fetal harm when administered to pregnant women.
- There are no available data on Synribo use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes.
- There are no data on the presence of omacetaxine mepesuccinate in either human or animal milk, the effects on the breastfed child, or the effects on milk production.
- Because of the potential for serious adverse reactions in the breastfed child, advise patients that breastfeeding is not recommended during treatment with
Synribo, and for 2 weeks after the final dose.